Limits...
The antihyperlipidemic mechanism of high sulfate content ulvan in rats.

Qi H, Sheng J - Mar Drugs (2015)

Bottom Line: For the male rats, compared with the hyperlipidemia group, the middle dosage HU had the most pronounced effect on increasing the mRNA levels of FXR (p < 0.01); low- and high-dosage HU showed a significant inhibition of the mRNA levels of LXR (p < 0.01).All HU female groups could upregulate the mRNA expression of PPARγ in a concentration-dependent manner.In summary, HU could improve lipid profiles through upregulation of FXR and PPARγ and downregulation of LXR.

View Article: PubMed Central - PubMed

Affiliation: Weifang Medical University, No.7166 Baotong Road, Weifang 261053, China. wfqihuimin@126.com.

ABSTRACT
Numerous studies have suggested that hyperlipidemia is closely linked to cardiovascular disease. The aim of this study was to investigate the possible antihyperlipidemia mechanism of HU (high sulfate content of ulvan) in high-cholesterol fed rats. Wistar rats were made hyperlipidemic by feeding with a high-cholesterol diet. HU was administered to these hyperlipidemia rats for 30 days. Lipid levels and the mRNA expressions of FXR, LXR and PPARγ in liver were measured after 30 days of treatment. In the HU-treated groups, the middle dosage group of male rats (total cholesterol (TC): p < 0.01) and the low-dosage group of female rats (TC, LDL-C: p < 0.01) showed stronger activity with respect to antihyperlipidemia. Moreover, some HU groups could upregulate the mRNA expression of FXR and PPARγ and downregulate the expression of LXR. For the male rats, compared with the hyperlipidemia group, the middle dosage HU had the most pronounced effect on increasing the mRNA levels of FXR (p < 0.01); low- and high-dosage HU showed a significant inhibition of the mRNA levels of LXR (p < 0.01). All HU female groups could upregulate the mRNA expression of PPARγ in a concentration-dependent manner. In summary, HU could improve lipid profiles through upregulation of FXR and PPARγ and downregulation of LXR.

No MeSH data available.


Related in: MedlinePlus

Food intakes of female rats (average, g/rat/day). 1: normal control group; 2: hyperlipidemia group; 3: ulvan group (250 mg/kg); 4: HU low dose group (125 mg/kg); 5: HU middle dose group (250 mg/kg); 6: HU high dose group (500 mg/kg); 7: positive group (cholestyramine, 500 mg/kg).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4483636&req=5

marinedrugs-13-03407-f004: Food intakes of female rats (average, g/rat/day). 1: normal control group; 2: hyperlipidemia group; 3: ulvan group (250 mg/kg); 4: HU low dose group (125 mg/kg); 5: HU middle dose group (250 mg/kg); 6: HU high dose group (500 mg/kg); 7: positive group (cholestyramine, 500 mg/kg).

Mentions: Changes in body weight during the administration period are shown in Figure 2. Values for all dose groups in both sexes were comparable to those of the controls groups. Except for hyperlipidemia groups, the other groups had no significant differences recorded throughout the administration period. At the end of the experimental period (30 days), both the male and female hyperlipidemia groups showed higher weight than the control group (p < 0.05). During the administration period, the averages of food intakes for each group were obtained. The results showed that there was no significant difference in food intakes between the ulvan (U), HU groups and normal control rats (Figure 3 and Figure 4).


The antihyperlipidemic mechanism of high sulfate content ulvan in rats.

Qi H, Sheng J - Mar Drugs (2015)

Food intakes of female rats (average, g/rat/day). 1: normal control group; 2: hyperlipidemia group; 3: ulvan group (250 mg/kg); 4: HU low dose group (125 mg/kg); 5: HU middle dose group (250 mg/kg); 6: HU high dose group (500 mg/kg); 7: positive group (cholestyramine, 500 mg/kg).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4483636&req=5

marinedrugs-13-03407-f004: Food intakes of female rats (average, g/rat/day). 1: normal control group; 2: hyperlipidemia group; 3: ulvan group (250 mg/kg); 4: HU low dose group (125 mg/kg); 5: HU middle dose group (250 mg/kg); 6: HU high dose group (500 mg/kg); 7: positive group (cholestyramine, 500 mg/kg).
Mentions: Changes in body weight during the administration period are shown in Figure 2. Values for all dose groups in both sexes were comparable to those of the controls groups. Except for hyperlipidemia groups, the other groups had no significant differences recorded throughout the administration period. At the end of the experimental period (30 days), both the male and female hyperlipidemia groups showed higher weight than the control group (p < 0.05). During the administration period, the averages of food intakes for each group were obtained. The results showed that there was no significant difference in food intakes between the ulvan (U), HU groups and normal control rats (Figure 3 and Figure 4).

Bottom Line: For the male rats, compared with the hyperlipidemia group, the middle dosage HU had the most pronounced effect on increasing the mRNA levels of FXR (p < 0.01); low- and high-dosage HU showed a significant inhibition of the mRNA levels of LXR (p < 0.01).All HU female groups could upregulate the mRNA expression of PPARγ in a concentration-dependent manner.In summary, HU could improve lipid profiles through upregulation of FXR and PPARγ and downregulation of LXR.

View Article: PubMed Central - PubMed

Affiliation: Weifang Medical University, No.7166 Baotong Road, Weifang 261053, China. wfqihuimin@126.com.

ABSTRACT
Numerous studies have suggested that hyperlipidemia is closely linked to cardiovascular disease. The aim of this study was to investigate the possible antihyperlipidemia mechanism of HU (high sulfate content of ulvan) in high-cholesterol fed rats. Wistar rats were made hyperlipidemic by feeding with a high-cholesterol diet. HU was administered to these hyperlipidemia rats for 30 days. Lipid levels and the mRNA expressions of FXR, LXR and PPARγ in liver were measured after 30 days of treatment. In the HU-treated groups, the middle dosage group of male rats (total cholesterol (TC): p < 0.01) and the low-dosage group of female rats (TC, LDL-C: p < 0.01) showed stronger activity with respect to antihyperlipidemia. Moreover, some HU groups could upregulate the mRNA expression of FXR and PPARγ and downregulate the expression of LXR. For the male rats, compared with the hyperlipidemia group, the middle dosage HU had the most pronounced effect on increasing the mRNA levels of FXR (p < 0.01); low- and high-dosage HU showed a significant inhibition of the mRNA levels of LXR (p < 0.01). All HU female groups could upregulate the mRNA expression of PPARγ in a concentration-dependent manner. In summary, HU could improve lipid profiles through upregulation of FXR and PPARγ and downregulation of LXR.

No MeSH data available.


Related in: MedlinePlus